Ashling Wahner

Articles

Cancer Vaccines Approach New Horizons in Melanoma and Other Solid Tumors

May 22nd 2024

Patrick Ott, MD, PhD, discusses the investigation of cancer vaccines, highlighting the clinical implications of this treatment modality in melanoma.

Inavolisib Receives FDA Breakthrough Therapy Designation for PIK3CA-Mutated, HR+/HER2– Breast Cancer

May 21st 2024

Inavolisib/palbociclib/fulvestrant was granted FDA granted breakthrough therapy designation for PIK3CA-mutated, HR-positive/HER2-negative breast cancer.

Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer

May 17th 2024

TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer

May 17th 2024

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

Repotrectinib Receives NMPA Approval in China for ROS1+ NSCLC

May 13th 2024

Repotrectinib has been approved by China’s National Medical Products Administration for the treatment of patients with ROS1-positive NSCLC.

Avutometinib Plus Defactinib Signals Changing Tides in Low-Grade Serous Ovarian Cancer

May 13th 2024

Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.

CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors

May 9th 2024

The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.

Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease

May 9th 2024

Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.

Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV

May 8th 2024

Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.

Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL

May 7th 2024

Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.

EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC

May 6th 2024

The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.

Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL

May 6th 2024

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024

Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.

Phase 2 Trial Closure Clears a Path for Accelerated Development of Stenoparib in Ovarian Cancer

May 3rd 2024

A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

May 2nd 2024

Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.

ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm

May 2nd 2024

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

May 1st 2024

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.